UK-based speciality enzyme company, Biocatalysts Ltd. has celebrated its 35th anniversary this year with a major investment into its future manufacturing capacity. Over £6 million (US$7.7 million) will be invested in total, comprising an 11,000 sq ft extension to the existing building which has just been completed. The next step is to fit out the building with cutting-edge equipment, including a 10m3 fermenter and down-stream processing machinery.
It will all be controlled by state of the art software to maximize their capacity and enhance efficiencies, “guaranteeing the world class support and service we provide.” The new production area, also offers future expansion capacity too, negating the need for the company to move.
Biocatalysts’ expanding technical and production teams will be key during this transition period, providing high end technical skills and project management support to ensure that the right first time philosophy of the company is upheld.
As well as the increased manufacturing capacity, Biocatalysts recently launched MetXtra, a unique enzyme discovery platform that provides a fast and cost-effective approach to novel enzyme development. Add into this mix the recent purchase of Biocatalysts by BRAIN AG, which further strengthens the company’s offering and gives customers access to “an unparalleled range of capabilities in enzyme discovery.”
Daren Bryce, Commercial Director at Biocatalysts, comments: “This represents a very exciting time in the speciality enzyme field. The unique breadth of offering, from discovery right through to large scale production, that Biocatalysts has to offer will allow previously in-accessible novel enzymes at commercial scale to our customers.”
